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PTCA in I~  ~ fixed 1"1 defect, Details were as fOllOWS; 
Grou~ 1 Gfou~ ~ P v~ 
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MLD Po~ (mini 2,32 t 048 2 .23 ,0  57 NS 
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%0~ P~ 630 z 16 2 80,4 * '110 NS 
~P0M 182 ~ 10.4 ~1 t 10.~ N~ 
~ppeam to w=~¢l~ ~ ch,~,,-,,~ c~naw pate~¢y attef PTCA 
Impm~ld I~ t lolplt l l  Oulmome lot ~ W~h 
~ Left ~ r  Oy~un~km who 
u~k.~w A~k,pm~ 
Pa!~m= ~ a Jow ~ ~ract~ 1~25%) who u~cle~o comMw argo- 
I~t~ am ~ ~ ~ We ~ Be h ,~ J~m mat me re~,~me~ 
m the le,~m~gy and the ~ of ~,-,m ~ m~m~e me ot~come 
m theee parlays+ ~ w e ~  t20 pa~ents ~ a fow ~ lractmn 
who ~ omor',a~ a* - - ,~  ¢1~ l~Bl-t~14 (Group I) to 47 pa- 
(Group II)_ The perce~ ol.."ah*m~ unnt iow qectmn hacto~ who ~ 
a~gmldaS~ mmmhve to llPze tolal p',,p. .  _~,,~.~ for lhe same Im~e period wa~ 
hlghor m group II (1+2% vts 0.6%, p < 0.0001). ~ d~ra¢lzm~i~ were 
ezgcept 11ol ~,1 ~ po~,~,_f--~ m grOUp It (65 v/S 61 years, p = 0 .~)  r 
Ao~lecfosureo¢¢tmed momhequem~ mgfoupl(17.5% vtS2.1%, p ~ 0.01). 
Slents m used more heq~ m gloup II (23+4% v/s 42%. 0 = 0+0(~4). 
The use o~ in l~ao~c h .~nn pump was sa~ax ~ be~ gn~p~ 12-5% v/s 
21. p = ns). In ~ co~ona~ ar~ bypa~z stege~/a~l daslh was morn 
commo~ m group I (10.~% v+ 0%, p : O02). One year e~,~nl Iree sunm,.al 
was 56% in g~up I and 54% m greup Ii (p = 02). 
Conc~/on- More pa in ts  ~ severe lelt veofncu~ have 
been aemmpeed wdh ~ m rece~ years. Tha hosp~ ou~-ome is 
moeasm~y more ~ .  Loc~:J lemt o~',.~,-~e needs to be e.v-a k.~a~L,d o~e.r 
a Io~ge~ pe~d ol ~m~e. 
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Adpmct~ treatment ol PTCA w~h ar.,,:.,.~,T, ab ~s a. ,~x~t~l w~th 
reductmns m early ,.,~w~ts. but the effects of p~atelat GP Ig~lla receplm" 
antagon~ Iberapy on ~mcal res len~s,  as detirmd by lato ta+,get vessel 
mvasculanzation (TVR), remains uncorlam as conflfcZmg ~ hame 
I~=e~ reached in recent n~dlJ~efstor t iala+ We souQt~t to ~ W4,XEH~Ier 
the striking re~ucti~t m perq~0cedural MI afforded by ab~L, mT~tb ~ con- 
found an accumle assessment ol the drug's effects on the need for lato TVR 
In the I~lCebO-CO~tro~ed EPIC toal. 2.099 patients wilh high-rrsk ~ or 
an~0graph¢ features underwent PTCA or alberecfomy and were ~,+o~:,¢-,:.- 
~.ely followed for 3 yearn. Within ~ study pol~dalm¢~. I ~  CK 
e levat~ was a sKj.ificant predictor of late modalily. Among patients w~n 
elevated CK, however, a paradoxical decrease in the need for late TVR 
was present. This relationship became ~ l y  mere profound as the 
megn i~ of CK release increased+ 
CK raho 3 y~ m:.rtalffy (%) 3 ~ ~ % (Rtsk Rabo. 9'5%CI) 
Normal 64 29 8 - 
1, nom~l 6.2 27.9 (0+92. O.-5-1.14) 
:2 • 6.4 25.4 (0.79. 060-1 03) 
~3, 76 24 8 (0.75. 0.55-1 01) 
"5~ 9 1 20.8 (062. O 42-092) 
"" lOx 10 4 16 .9  (051.0.29-O.91) 
Is ~ r  Int~xttMIon m ~ I ,b An, ly, ls 
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l : v ln t l  A t i l t  P f lml ry  PT~A?  
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>+ ~ ~,+~ ~,~:~d~ ~ m ~ ~ .  O ~  ~ ~ ~ 
in+hol4t~al ~ MI, or a~hem~ Pnma~ FrC.,A was I~ffomted m 9116 
pa l~,  of whom 1.9",. had mMI and 10Ji% had ~ ~ e~ly ee~ 
la~ o~ ~ o~ mMI was m~l  mt~a~s ~30% or ~ we#eece ota 
TIMI Ik.w+ am+ ~',,T.-,--4X+S 7~te  were not pmdtct~m, 
Rec~em Mt P ra te  CI' P vaJue Cf 
SIm*'mms 00015 0¢~0 00007 P. ,~,~ 
Demecl~m~ 0 (X]O? O.~l NS 
0004 0~,~, 0CO~ 
O0t 025 NS 
016 
" ~  comaCn~ ~'4~ez iSomenr,' D) = be~e~ pe~l¢l~ al~rdy 
T~'efo~. opma~ m~eq~aaon appea~ to be supe~ fo corn ~a 
ana~y~ m pred¢-mg .~ho~d nacunent acbe~a or .m~fameon. Whee~ 
mm is clue to use ol gonmscopc findings ~ch  were nm mcomed on cme, 
acu~ usa of d,g*la~ m~0m~ or gmat~ ~r ' ,~r  e.,¢meeece desemam fu~her 
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Backgrmm~ We have immm~my dem,.,m+,,,~ed m-vain that mhefmckmmc 
(ATI-q aJrtsnal trireme +,,~, sour¢l as it expanencas meclwnmal dmmlmon. 
Me~floo~: TO fodl~r cbaraclenze acoustic + v ~  (AE) pmllems and 
to ~;y  tf AlE occur m-v~vo at the ~e of begoon a n ~  (BA), 24 
human atonal speomens oblamed post-mort~ and 8 ATH asd conlrel at. 
tenes m~wNo (n~zJswme) were evaluated Artones were ~ lo BA wflh 
s,~naneous moo ing  o( AlE usn~ a ~ i~=eele¢l~ ~a,~- 
dm+-e+. The recorded +~,-,~Is were m-~ized m IM Imme domain using we.,mCet 
teG-.-,Cmes and m lhe frequency domain using Fourier t,~+%-,~p+as, and
chamctmzzed a,~:,+~G.-~j m tbe t~e of ,~_ _,c~J trauma using K,+,~.+,-.+,+ neural 
rmtwork ~ 
P.est.dls: Vascular AIE were demormtraled to occur be;-,~,m~,-+ 30 and 5000 
Hz+ Umng q~m:trograms wilh Koh+.-,~ dasmfmaZton, lhe sounds were char- 
aclenzed as no~eeless, plaque Iraclzae aml lasrlng. The io-vwo dala i+~¢afe 
fewer ex1~-,~us r:,~,~-,as nd 1ha same AE ~ as ,~-~-,~d in ff~e + 
v~ro s~dms. Tean.g m ~ w~ rela1~ely Ion9 (0.4-1,0S) ~;~r+'  
AE. pagoo~ opor,ng with shoder and lower frequency AE. and frectum wi1~ 
even sha,ler (0.1 s) and "c~per' AE 
Conctus~n: We have demonstrated mat vascular ecous~ emtssk~ 
eccur fogo~ng amemma mjury bom m-vitro and m-~vo. Wavefo~n ar~/m 
helps to ~ r  dL~bngutsh normal from pat t~ vascular iojury. ~ data 
supparl the ~- ,c~ of ush'Kj a¢ous~ em=sions as a meens of mor~ortng 
and optin'nzing balloon anojol~asty 
Mechanistically. while it is unlikely that CK elevation prevents vascular 
renanowing per se. myocardial necrosis impairs the clinical manifestation of 
restenosis, thereby reducing the need for ischemia-driven "l V'R. 
Conclusion: In the EPIC study, patients with pariprocedural MI were less 
likely to develop clinical restenosis as measured by the need for TVR at 3 
years. This novel finding (1) highlights a mechanism for potential discordance 
between anglographic and clinical measures of restenosis, and (2) has im- 
plications for future clinical trials, as therapies which reduce periprocedurat 
MI may be associated wit,1 a perceived excess of restenosis when moasured 
by the need for TVR+ 
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